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Abstract
Background: Atrial natriuretic peptide (ANP) is an important endogenous hormone that controls inflammation and
immunity by acting on dendritic cells (DCs); however, the mechanism remains unclear.
Objective: We analyzed the downstream signaling events resulting from the binding of ANP to its receptor, NPRA,
and sought to determine what aspects of this signaling modulate DC function.
Methods: We utilized the inhibitory peptide, NP73-102, to block NPRA signaling in human monocyte-derived DCs
(hmDCs) and examined the effect on DC maturation and induced immune responses. The potential downstream
molecules and interactions among these molecules involved in NPRA signaling were identified by
immunoprecipitation and immunoblotting. Changes in T cell phenotype and function were determined by flow
cytometry and BrdU proliferation ELISA. To determine if adoptively transferred DCs could alter the in vivo immune
response, bone marrow-derived DCs from wild-type C57BL/6 mice were incubated with ovalbumin (OVA) and
injected i.v. into C57BL/6 NPRA-/- knockout mice sensitized and challenged with OVA. Lung sections were stained
and examined for inflammation and cytokines were measured in bronchoalveolar lavage fluid collected from
parallel groups of mice.
Results: Inhibition of NPRA signaling in DCs primes them to induce regulatory T cells. Adoptive transfer of wild
type DCs into NPRA-/- mice reverses the attenuation of lung inflammation seen in the NPRA-knockout model.
NPRA is associated with TLR-2, SOCS3 and STAT3, and inhibiting NPRA alters expression of IL-6, IL-10 and TGF-b,
but not IL-12.
Conclusions: Modulation of NPRA signaling in DCs leads to immune tolerance and TLR2 and SOCS3 are involved
in this induction.
Introduction
Allergic asthma is a chronic inflammatory disease of the
lung, involving an aberrant T helper-2 (Th2) immune
response to allergens. The etiology of asthma is complex
and involves a number of signaling molecules and path-
ways as well as environmental factors. Atrial natriuretic
peptide (ANP) is a cardiac hormone that regulates
blood pressure and volume and the sodium/potassium
balance. Atrial natriuretic factor is synthesized as a pro-
hormone that is cleaved into a C-terminal peptide,
ANP, and a group of three N-terminal peptides which
are released into the circulation and may negatively
inhibit ANP activity. ANP binds to a cell surface recep-
tor, natriuretic peptide receptor A (NPRA), which is
found on cells in the lung and airways as well as kidney
and other tissues. Hormone binding to NPRA is the pre-
dominant trigger in the natriuretic system and generates
the intracellular signaling molecule cyclic guanosine
monophosphate (cGMP) which can activate cGMP-
dependent protein kinase and initiate a cascade of
events. Patients with asthma or inflammatory lung
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which suggests that manipulation of NPRA signaling
might provide a therapeutic benefit for asthmatics [2].
The natriuretic peptide family comprises atrial
natriuretic peptide, ANP, brain natriuretic peptide, BNP,
C-type natriuretic peptide, CNP, Dendroaspis natriuretic
peptide, DNP, and urodilatin [3]. The activities of ANP
and BNP are similar, and their biological actions, such
as vasodilation and natriuresis, are mediated through
binding to their receptor, NPRA, which leads to produc-
tion of the intracellular second messenger cGMP [4].
Besides expression in heart atria, ANP is also produced
in various lymphoid organs [5], and the NPRA receptor
is found on immune cells of numerous species high-
lighting the importance of NPRA signaling in the
immune response [6].
Over-production of ANP can affect the adaptive
immune system by altering dendritic cell (DC) differen-
tiation and promoting a Th2 response characteristic of
allergic disease [7]. However, the mechanism by which
NPRA signaling in DCs alters the innate and adaptive
immune responses is unclear. In animal models of aller-
gic lung inflammation, we showed that ANP signaling
through NPRA promotes lung histopathology [8]. In
studying the regulation of NPRA, we discovered a pep-
tide, NP73-102, from the N-terminus of the ANP pro-
hormone that acts as a brake on ANP signaling by
reducing expression of NPRA. NP73-102 consists of
amino acids 73 to 102 of the ANP prohormone and has
bronchoprotective effects in a mouse model of asthma
and anti-inflammatory activity in human epithelial cells
[9]. The amino acid sequence of this peptide is different
from ANP and NP73-102 does not bind to NPRA and
prevent ANP from attaching. NP73-102 reduces ANP-
induced signaling by downregulating its receptor and by
feedback inhibition of ANP production [10].
DCs express abundant NPRA while macrophages do
not. It was therefore hypothesized that the effects of
NPRA signaling on innate and adaptive immunity occur
through NPRA-mediated alterations in gene expression
in DCs. Little is known about the role of NPRA signal-
ing in innate immunity and about the downstream
effects of NPRA-mediated immunoregulation in DCs.
Tolerogenic DCs present antigen to T cells, but do not
deliver the signals for effector T-cell activation and pro-
liferation. This lack of costimulation can result in T-cell
apoptosis [11], T-cell anergy [12] or differentiation into
regulatory T-cells (Tregs) [13]. The identification of
ANP’s effects on DCs as key regulators of peripheral tol-
erance to allergens may be important in the prevention
and treatment of allergic diseases [14,15].
In this study, the NPRA inhibitory peptide NP73-102
was utilized to block NPRA signaling in human DCs
and to analyze the downstream cascade events. The
results demonstrate that Toll-like receptor-2 (TLR2) and
suppressor of cytokine synthesis-3 (SOCS3) are key
players in integrating NPRA signaling with innate
immunity and in the induction of tolerogenic DCs.
Materials and methods
Isolation, transfection and viability assay of human
dendritic cells
Human monocytes were isolated from peripheral blood
mononuclear cells using the Monocyte Isolation Kit II
(Miltenyi Biotec, Auburn, CA). Human monocyte-
derived DCs (HmDCs) were generated from these cells
as previously described [16]. Briefly, monocytes isolated
from peripheral blood mononuclear cells were induced
to differentiate into DCs by incubation with 200 ng/ml
IL-4 and 50 ng/ml GM-CSF. Five day-old DCs were
transfected with the indicated plasmid (3 μg/10
6 cells)
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
After 24 hr, cell viability was measured by MTT assay
(Sigma/Aldrich, St Louis, MO). Additional information
on the viability assay is provided in Additional File 1.
Cytokine measurement
Transfected hmDCs (1 × 10
6 cells/well) were cultured in
24-well plates for 24 h. Cytokine levels in the cell-
culture supernatants were measured using a cytokine bead
array kit (BioSystem, Bio-Rad) following the manufac-
turer’s directions. All samples were assayed in duplicate.
Isolation of naïve T cells, generation of Tregs and T-cell
suppression assay
Human allogeneic naïve CD4+CD25-T cells were puri-
fied from umbilical cord blood using the naïve T cell
isolation kit with biotinylated CD25 antibody (Miltenyi
Biotec, Auburn, CA) and co-cultured with irradiated
transfected hmDCs (10:1 ratio) in 24-well plates for
6 days. Expression of the Treg protein FoxP3 by co-
cultured T cells was quantitated by flow cytometry (BD-
FACScan, BD Biosciences, San Jose, CA). Also, total
RNA was extracted and analyzed by reverse transcrip-
tase-PCR for FoxP3. Tregs were purified with the Treg
cell isolation kit (Miltenyi Biotec.) and a co-culture sup-
pression assay was performed using a BrdU proliferation
ELISA kit (Roche, IN, USA) as previously described
[17]. Additional information is provided in the Addi-
tional File.
Measurement of intracellular cGMP
Five day-old hmDCs (10
6 cells/sample) were transfected
with the indicated plasmid and incubated in medium for
18 h. After incubation, the cells were removed from the
plate, pelleted by centrifugation (750× g, 5 min) and
intracellular cGMP in the cell pellets was measured with
a cGMP ELISA kit (R & D Systems, Minneapolis, MN).
Zhang et al. Genetic Vaccines and Therapy 2011, 9:3
http://www.gvt-journal.com/content/9/1/3
Page 2 of 12Phagocytosis assay
Five day-old hmDCs (10
6) were harvested 24 hr post-
transfection and resuspended in RPMI 1640 medium
supplemented with 2% FBS. The FITC-dextran phagocy-
tosis assay was performed as described [18].
Immunoprecipitation and immunoblotting
Five day-old hmDCs were transfected with 3 μge a c ho f
expression plasmid encoding NPRA, TLR2, STAT3 and
SOCS3 and then harvested 24 hr post-transfection.
Lysates (400 μg of protein/sample) were immunoprecipi-
tated with antibody against TLR2, STAT3, SOCS3 or
NPRA overnight at 4°C. The antibody complexes were
precipitated by the addition of recombinant protein G
agarose (Invitrogen, Carlsbad, CA). Eluted proteins were
resolved on 12% SDS-PAGE gels, transferred to PVDF
membranes (Bio-Rad, Hercules, CA) and immunoblotted
with the indicated antibodies.
Luciferase assay
HmDCs were transfected with the indicated plasmid and
48 h later, the cells were analyzed for luciferase activity.
Additional detail is provided in the Additional File.
Studies in mice: OVA sensitization, DC isolation and
adoptive transfer
Bone marrow cells were removed from C57BL/6 NPRA-/-
or wild type (WT) mice and cultured for 8 days as
described previously [19]. Bone marrow-derived DCs
(bmDCs) were purified using CD11c microbeads (Miltenyi
Biotec, Auburn, CA), incubated with ovalbumin (OVA;
0.5 mg/ml) for 24 hr and injected i.v. into NPRA-/- mice
(5 × 10
6 bmDCs/mouse), which had been sensitized (i.p)
and challenged (i.n) with OVA (25 μg). Mice were eutha-
natized, lungs were lavaged with 1 ml of PBS, and BAL
cytokines were quantitated by cytokine bead array (BioSys-
tem, Bio-Rad, Hercules, CA). Lung histopathology was
assessed using a previously described scoring system [20].
Additional details are provided in the Additional File.
Statistical analysis
The results are expressed as means ± SEM. Data were
analyzed using an unpaired two-tailed Student’s t test.
Results
NP73-102 inhibits NPRA signaling in human DCs
Both endogenous ANP and NPRA are expressed by cul-
tured hmDCs (Figure 1A). Transfection of hmDCs with
pNP73-102, however, decreases the expression of endo-
genous ANP and NPRA compared to controls (Figure
1A). To determine if NP73-102 overexpression caused
cytotoxicity in DCs, cell viability was measured 24 hr
post-transfection. NP73-102 did not significantly affect
cell viability at the dose used (Figure 1B). Intracellular
cGMP levels in transfected hmDCs were also measured
at 18 hr post-transfection. NP73-102 dose-dependently
decreased cGMP production by blocking the activity of
endogenous ANP compared to controls (Figure 1C),
indicating that NP73-102 inhibits NPRA signaling in
human DCs. The transfection efficiency of hmDCs
transfected with pEGFP, as assessed by fluorescence
microscopy of green fluorescent protein, was 41.3%.
Inhibiting NPRA signaling alters cytokine production in
human DCs
As demonstrated in Figure 1A, hmDCs produce endo-
genous ANP that can be down-regulated by NP73-102.
Activation of the ANP-NPRA signaling pathway can
alter cytokine profiles in hmDCs and inhibiting this
pathway with pNP73-102 allowed greater production of
IL-6, IL-10 and TGF-b ( F i g u r e2 A& 2 B ,E& 2 F ) .I L - 1 2
and IFN-g levels did not change significantly among the
groups (Figure 2C &2D).
Inhibiting NPRA signaling in human DCs induces Tregs
Since blocking NPRA signaling by transfection of
hmDCs with pNP73-102 up-regulates IL-10 and TGF-b
expression, the role of NPRA in Treg induction was
investigated. HmDCs were transfected with pNP73-102,
pANP or pVAX and cocultured with allogeneic naïve
CD4+ CD25-T cells (FoxP3-negative by RT-PCR).
NP73-102 induced more FoxP3 expression than did
ANP or vector alone (Figure 3A &3B). NP73-102-
induced CD25+ T cells were able to suppress prolifera-
tion of CD4+CD25-T-cells in a dose-dependent manner
(Figure 3C), suggesting that CD4+CD25+ T cells with
suppressive ability can arise from CD4+CD25-naïve T
cells co-cultured with NP73-102-treated hmDCs, corre-
lating with the expression of FoxP3.
Inhibiting NPRA signaling does not affect maturation of
human DCs
The degree of hmDC maturation affects their capacity
for Treg generation, and therefore the NPRA signal
blockade was investigated to see if it alters hmDC
maturation. Using the ability to phagocytose as a mea-
sure of maturation, pVAX or mock transfection slightly
lowered hmDC phagocytosis compared to pNP73-102 or
pANP (Figure 3D). Further, the hmDC phenotype analy-
sis showed that HLA-DR, CD11c, CD40 and CD80 did
not significantly change in expression among the groups
(Figure 3E), suggesting that NPRA signaling does not
affect hmDC maturation.
NPRA inhibition alters expression of TLR-2, STAT3 and
SOCS3 in human DCs
IL-6 operates through the JAK1-STAT3 pathway, and
triggering TLRs on mouse DCs can induce SOCS1
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show that transfection with pNP73-102 down-regulated
the level of activated phospho-STAT3 protein and
enhanced expression of SOCS3 (Figure 4A), but not
SOCS1 (data not shown). pNP73-102 selectively decreased
TLR2 expression on DCs while elevating MyD88 com-
pared to pANP or pVAX. We also found that pNP73-102
reduced the NF-B transactivation from a promoter con-
struct in hmDCs (Figure 4A). To confirm this effect, a
luciferase reporter system was utilized to test the effect of
NPRA inhibition on promoter activity of some target
genes. As shown in Figure 4B-D, NP73-102 attenuated the
activity of STAT3/NF-B and increased the activity of
SOCS3 in hmDCs.
Protein interactions in the NPRA signal pathway
This set of experiments was designed to determine which
of the proteins that are known to be involved in DC
function might be associated with NPRA. The hmDCs
were transfected with NPRA, TLR2, STAT3 and SOCS3
expression plasmids, allowed to express for 24 hr, then
whole-cell lysates were immunoprecipitated with the
indicated antibody. The levels of expression of each of
the proteins in the transfected cells were approximately
the same as shown by the second set of bands in each IP.
Precipitates were recovered and eluted proteins were
separated by SDS-PAGE and immunoblotted for the indi-
cated protein (first set of bands). The blots showed that
NPRA was strongly pulled down with TLR2 and STAT3
and weakly with SOCS3 (Figure 5A). The corresponding
bidirectional pull-down assays were done and showed
similar results (data not shown). TLR2 was bound to
STAT3, and the adaptor protein MyD88 bound both
STAT3 and SOCS3 (Figure 5A). The IP data suggest that
the immunoregulation of NPRA signaling in hmDCs may
involve a specific interaction among these four proteins
Figure 1 NP73-102 is an inhibitor of NPRA signaling in hmDCs. (A) HmDCs were transfected with the indicated plasmids. The cells were
collected 24 hr after transfection, lysed and immunoblotted with the indicated antibodies. (B) Cell viability of hmDCs by MTT assay 24 hr after
plasmid transfection. (C) HmDCs were transfected with different doses of the indicated plasmids. The cells were collected 18 hr after transfection
and intracellular cGMP was measured by ELISA. Analyses shown are representative of two or three independent experiments.
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medium in 24-well plates for 24 hr. Cytokine levels in supernatants were measured in duplicate by cytokine bead array assay. The values are
means ± SEM. *p < 0.05 and **p < 0.05 for NP73-102 vs pVAX and pANP respectively. (E) Immunoblotting for TGF-b expression in transfected
DCs. (F) Protein bands were scanned and band density was quantitated using the Scion Image program. These results are from three separate
experiments.
Zhang et al. Genetic Vaccines and Therapy 2011, 9:3
http://www.gvt-journal.com/content/9/1/3
Page 5 of 12Figure 3 Modulation of NPRA signaling in human monocyte-derived dendritic cells (hmDCs) alters Treg generation in vitro. (A) Flow
cytometry assay for Foxp3-positive T cells in naïve CD4+ CD25-T cells co-cultured with plasmid-transfected hmDCs. Results shown are from one
representative experiment of three repeats. (B) RT-PCR analysis of Foxp3 expression in naïve CD4+ T cells after co-culture with plasmid-
transfected hmDCs. (C) Autologous CD4+CD25-T cells were co-cultured with NP73-102-induced CD4+CD25+ T cells at different ratios and the
proliferation index (PI) was calculated. (D) Phagocytosis by hmDCs transfected with the various plasmids. DCs were harvested one day after
transfection, incubated with FITC-dextran for 1 h at 37°C and counted by flow cytometry. For each sample, the background (mean value of
fluorescence of cells exposed to FITC-dextran at 4°C) was subtracted from the mean value of fluorescence of hmDCs incubated at 37°C. (E) Flow
cytometric analysis of phenotypic markers of transfected hmDCs. Results shown are from one representative experiment of three repeats.
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figuration that fits the observed association data, but
further work is needed to clarify whether ANP binding to
NPRA influences TLR2 activation or vice versa and how
NP73-102 might alter the protein interactions.
Adoptively transferred wild type mouse bone marrow-
derived DCs (bmDCs) restore lung inflammation in
NPRA-/- mice
Since hmDCs express NPRA [7] and NP73-102 prevents
NF-B activation in hmDCs in vitro (Figure 4A, D), we
reasoned that alterations in NPRA signaling in DCs
should affect inflammation in vivo. To test this hypoth-
esis, OVA-treated bmDCs from NPRA-/- or WT
C57BL/6 were adoptively transferred into NPRA-/- mice
that had been sensitized and challenged with OVA. As
s h o w ni nF i g u r e6 A ,t h el u n g sf r o mN P R A - / -m i c e
given bmDCs from wild-type mice exhibited inflamma-
tion similar to that of WT; however, OVA-treated
NPRA-/- mice given no bmDCs or given bmDCs from
NPRA-/- mice had little lung inflammation, suggesting
that NPRA signaling in DCs plays a critical role in allergic
Figure 4 Natriuretic peptides modulate the expression of TLR2, STAT3 and SOCS3 in hmDCs. (A) HmDCs were transfected with the
indicated plasmids, and cells were collected 24 hr after transfection for protein immunoblotting. (B-D) SOCS3, STAT3 and NF-B reporter
activities in DCs were measured after natriuretic peptide stimulation. The results shown are representative experiments from three independent
assays.
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observers of lung sections under the microscope (Figure
4B) confirmed the visualized results of Figure 4A. Cyto-
kines were measured in BAL fluid collected from parallel
groups of mice, and the results show that NPRA-/- mice
given no bmDCs or given bmDCs from NPRA-/- mice
have decreased expression of IL-4, TNF-a and RANTES,
and increased IL-10 expression compared to other groups
(Figure 6C).
Discussion
A novel mechanism for inducing tolerogenic DCs by
inhibition of NPRA signaling in DCs is described. Our
demonstration that down-regulation of NPRA levels and
reduction in NPRA signaling in DCs increases the popu-
lation of Tregs may have important applications in
treating respiratory disease and inflammatory conditions.
Effective allergen immunotherapy involves generation of
Treg cells, and targeted NPRA down-regulation may be
used as a means to develop tolerogenic DCs that induce
Tregs to ameliorate or prevent inflammation.
The discovery of the NPRA inhibitory peptide NP73-
102, which reduces expression of NPRA and inhibits
NPRA signaling and the activation of several pro-inflam-
matory transcription factors in epithelial cells [8,9], has
provided the impetus to study the mechanism of how
NPRA signaling affects inflammation and immunity.
Increased NPRA signaling in DCs leads to a Th2 response,
Figure 5 Protein interaction analysis. (A) HmDCs were harvested one day after transfection with the indicated plasmid. Cell lysates were
immunoprecipitated (IP) with antibody against TLR2, STAT3, SOCS3 or NPRA and immunoblotted (IB) with STAT3, SOCS, MyD88, or NPRA
antibodies, respectively. A representative experiment from three independent assays is shown. (B) Diagram of hypothesized protein interactions
in the immune response associated with NPRA signaling in hmDCs.
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Figure 6 Adoptive transfer of bone marrow-derived DCs (bmDCs) from WT mice increases inflammation in NPRA-/- mice.E i g h td a y -
cultured bmDCs generated from WT or NPRA-/- C57BL/6 mice were incubated with OVA for 24 h and injected i.v. into C57BL/6 NPRA-/- mice
(5 × 10
6 DCs/mouse) that had been sensitized and challenged with OVA. On day 8 after adoptive transfer, mice were sacrificed and lung
sections were stained with H & E and examined under the microscope for histopathology (A). Lung pathology was also scored according to a
1-5 severity scale (B). Cytokines were measured by cytokine bead array assays in BAL fluid collected from parallel groups of mice (C). Data shown
are representative of two experiments with similar results.
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induces more IL-10 and TGF-b production and stimulates
Treg formation.
Using an in vitro T cell-DC coculture system, down-
regulation of NPRA by NP73-102 resulted in greater
DC-mediated generation of Tregs. Analysis of DC sur-
face marker expression and in vitro phagocytosis
demonstrated that DC maturation was not significantly
affected by NPRA signaling blockade. The mechanism
underlying the NP73-102-induced Treg response is not
fully understood. It may be due to inactivation of
NF-B activity by NP73-102 inhibition of NPRA signal-
ing, since inhibition of NF-B in DCs enhances their
tolerogenic activity and prevents detrimental autoim-
mune diseases [22].
These data demonstrate that pNP73-102 increases the
level of IL-10 and TGF-b,b u tn o to fI L - 1 2a n dI F N - g,
compared to cells given pANP or vector alone. TGF-b,
which inhibits Th1 and Th2 development, is critical in
Th17 development, in combination with IL-6 [23] and
leads to the generation of Foxp3-positive regulatory T
cells [24]. However, there was no increase in the num-
ber of Th17 lymphocytes, even in the presence of IL-6,
in the DC-naïve T cell co-culture system, suggesting
that Tregs may inhibit Th17 generation or that different
cytokine profiles may produce diverse outcomes [25]. As
shown in Figure 3A, the pANP-treated group also
induced few Tregs versus the empty vector control,
suggesting that TGF-b m a yb ei n v o l v e di nt h ep r o c e s s
(Figure 2E &2F). However, attenuation of NPRA signal-
ing by pNP73-102 induced a greater amount of SOCS3
and generated more Tregs which supports the hypoth-
esis that ANP signaling effects are mediated through
production of tolerogenic DCs. Data show that ANP
inhibits TGF-b-induced Smad2 and Smad3 nuclear
translocation in rat pulmonary arterial smooth muscle
cells [26], which is consistent with our finding that ANP
induced less TGF-b production in human DCs than
NP73-102.
The SOCS3 protein was strongly induced by both IL-6
and IL-10. SOCS3 selectively inhibits IL-6 signaling via
its binding to the IL-6 receptor, but does not inhibit the
IL-10 receptor [27]. The suppressive effect of SOCS3 is
primarily restricted to STAT3 [28], and these results
show that pNP73-102 inhibits STAT3 activity and
enhances SOCS3 expression. This is in marked contrast
to pANP and the vector control, which induce STAT3
phosphorylation and decrease SOCS3 expression in
hmDCs. These data further support the idea that in this
model, NPRA signaling in tolerogenic DCs involves the
regulation of SOCS3 expression and STAT3 activity.
Cells exposed to pNP73-102 selectively diminished
TLR2 expression compared to cells given pANP or vec-
tor. This could be explained by decreased NF-B-
mediated down-regulation of TLR through a binding
site for NF-B on the TLR2 promoter [29]. Reports
have indicated that down-regulation of both TLR4 and
TLR2 expression in mice decreases the expression of
inflammatory cytokines and enhances production of
anti-inflammatory cytokines, which induce immune tol-
erance [30]. Significantly, enhanced MyD88 expression
was found in DCs treated with pNP73-102 compared to
pANP and vector control. An LPS-inducible MyD88 is
defective in its ability to induce IRAK phosphorylation
and behaves as a dominant-negative inhibitor of LPS-
induced NF-B activation [31]. Also, MyD88-knockout
mice show significantly reduced expression of SOCS3
[32], which is in part consistent with our data, although
it is unclear why pANP induced higher SOCS3 expres-
sion in the absence of MyD88 than vector control.
Thus, the enhanced expression of both SOCS3 and
MyD88 in DCs may be associated with a reduced
response to ANP, whereas the specific enhancement of
SOCS3 and/or MyD88 expression may explain the gen-
eration of tolerogenic DCs.
Indirect inhibition of JAKs due to the binding of
SOCS to membrane proximal regions of receptor chains
results in steric hindrance of constitutive JAK binding to
the receptor [33]. Inhibition of NPRA signaling by
pNP73-102 through SOCS3 might occur by this
mechanism. The IP data support this hypothesis. NPRA
binds to SOCS3, and this interaction might contribute
to the effects of NPRA signaling on immunoregulation.
NPRA also binds to TLR2 and STAT3. However, TLR2
and SOCS3 involvement in regulation of NPRA expres-
sion (unpublished data) might result from these protein
interactions rather than STAT3 involvement. Further
work is needed to clarify whether the interactions
among these proteins are direct or indirect.
In our animal model, we found that NPRA-/- mice
had decreased expression of Th2-like cytokines, and that
adoptive transfer of DCs from WT to NPRA-/- mice
restored levels of these cytokines to those seen in WT.
This is an important finding since it complements the
in vitro results in an animal model. The lungs from
NPRA-/- mice given DCs from WT mice exhibited
inflammation similar to that of the WT. OVA-treated
NPRA-/- mice given no DCs or given DCs from
NPRA-/- mice did not have significant lung inflamma-
tion (Figure 6A, B), suggesting that DCs are the key
mediators in modulating lung inflammation by NPRA
signaling.
Taken together, our results demonstrate a novel
mechanism for integration of TLR2, STAT3 and SOCS3
with NPRA signaling to regulate the immunomodulatory
activity of DCs. They support the hypothesis that inhibi-
tion of NPRA signaling and TLR2 expression in DCs
induces more IL-10 and TGF-b secretion and increases
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Treg cells.
Additional material
Additional file 1: Additional file 1. This supplementary material
contains additional information about the viability assay, the T cell
suppression assay, the luciferase assay, and the experiments in mice.
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